# AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

> **NCT02440568** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Illinois at Chicago** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Omacetaxine mepesuccinate
- **DRUG:** Omacetaxine mepesuccinate
- **DRUG:** Omacetaxine mepesuccinate
- **DRUG:** Omacetaxine mepesuccinate

## Key facts

- **NCT ID:** NCT02440568
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-05
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440568, "AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02440568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*